Načítá se...
Economic Outcomes Related to Persistence and Dosing of Celecoxib in Patients with Osteoarthritis (OA) Using a Retrospective Claims Database Analysis
OBJECTIVE: This study describes treatment patterns, healthcare resource utilization (HCRU), and costs associated with persistence, switching, and dosing of branded celecoxib in osteoarthritis (OA) patients. METHODS: This retrospective claims database analysis used MarketScan(®) Commercial Claims and...
Uloženo v:
| Vydáno v: | Clinicoecon Outcomes Res |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6982435/ https://ncbi.nlm.nih.gov/pubmed/32021340 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S199145 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|